Pharma Major Lupin has launched Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.
The company’s Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Epzicom tablets had US sales of $388.1 million according to IMS MAT December 2016.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.